Clearbridge BioMedics  
Clearbridge Biomedics 专精应用于肿瘤科学研究与诊断的创新平台开发。
Clearbridge Biomedics 是新加坡国立大学衍生公司，运用研究伙伴的创新技术，致力于革命性的癌症诊断与病患照护相关医疗器材开发。
ClearCell 系统由专利申请中的CTChip 组成，可以有效的从小量病患血液检体侦测并分离完整的循环肿瘤细胞。分离出的循环肿瘤细胞可直接在CTChip 染色进行鉴定与计数，或是取
出进行更进一步的分子分析。 ClearCell 系统的目标是成为癌症检验、分期以及监控提供新世代非侵入性液态切片的革命性平台。
Clearbridge Biomedics 的总部位于新加坡，客户遍布亚洲、欧洲与北美洲。

Clearbridge BioMedics (CBB) is a spin-off from National University of Singapore (NUS) and is also the first incubatee of Clearbridge Accelerator, a Singapore Government (National Research Foundation) backed high-technology incubator. CBB is also a successful recipient of SPRING Singapore’s Technology Enterprise Commercialisation Scheme (TECS) Proof-of-Value (POV) Grant.

Leveraging on a patent-pending microfluidic biochip invention, our ClearCell™ System, comprising the ClearCell™ Unit and a range of CTChips®, are able to effectively detect and isolate wholly intact Circulating Tumour Cells (CTCs) from patients' blood samples. CTCs are extremely rare cancer cells that have detached from a primary tumour and are circulating in the bloodstream. Capturing and counting CTCs could enable clinicians to conduct cancer screening, diagnosis and post-cancer monitoring that will be invaluable in allowing clinicians to make timely and life-saving decisions. Most impressively, the ClearCell™ System is able to capture and retrieve these CTCs, allowing researchers to conduct critical genetic analysis to optimise cancer therapies, paving the way for personalised cancer treatment.

The ClearCell™ System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medicine, and treatment monitoring.

Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

Our Mission

Clearbridge BioMedics’ mission is to innovate and develop novel medical research tools and diagnostic products using cutting-edge technologies, in order to catalyse medical research and discovery, revolutionise disease management, and advance patient care.